The National Institutes of Health (NIH), under the U.S. Department of Health and Human Services, has released a forecasted grant opportunity for a single-source competition aimed at continuing support for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) Resource Center. This initiative is a collaborative effort by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI), underscoring the NIH’s commitment to advancing biomedical research focused on diabetes and cardiovascular health. The CaRe-T1D biorepository, originally launched in 2020 through RFA-DK-21-010, and further expanded in 2024 via RFA-DK-23-021, has played a vital role in the collection, analysis, and dissemination of cardiovascular tissue samples from organ donors with type 1 diabetes (T1D), type 2 diabetes (T2D), and without diabetes.
This forecasted funding opportunity intends to support the ongoing operation of the CaRe-T1D Resource Center. The project seeks to facilitate the collection and analysis of cardiovascular tissue—including hearts, aortas, carotid arteries, and kidneys—while also maintaining and expanding the related data repository. The tissue samples and resulting data are used by the broader CaRe-T1D consortium for multi-omics and molecular research focused on the pathogenesis of cardiovascular disease (CVD) in people with T1D. By comparing cardiovascular disease mechanisms among those with T1D, T2D, and individuals without diabetes, the research aims to generate critical insights that could eventually lead to the development of novel therapies to mitigate CVD-related mortality in T1D populations.
The CaRe-T1D Resource Center plays a central coordination role, providing infrastructure for data sharing and scientific collaboration across the consortium. This includes ensuring data quality, managing biospecimen logistics, and facilitating communication among researchers. The Resource Center is also responsible for data integration from consortium projects and overseeing harmonized protocols that enhance reproducibility and data utility.
This is a single-source competition, meaning that NIH intends to invite application(s) from eligible organization(s) with demonstrated capacity and prior involvement with CaRe-T1D activities. Applications will be subject to NIH’s standard peer-review process, and only those deemed scientifically meritorious will be considered for funding. While a specific organization is not named in this forecast, eligibility will be narrowly defined and may be limited to current or previous participants in the CaRe-T1D network.
No cost-sharing or matching funds are required for this opportunity. Applications will be due on July 1, 2026, with an anticipated award and project start date of February 1, 2027. The total expected funding available is $2,000,000, and one award is anticipated. No clinical trials are permitted under this U24 cooperative agreement mechanism. Prospective applicants should monitor Grants.gov for the official Notice of Funding Opportunity (NOFO) publication to confirm eligibility and application requirements.
For additional information, interested parties may contact Dr. Teresa L. Z. Jones at [email protected] or via phone at 301-435-2996. As this is a forecasted opportunity, no application materials are currently available, but a full announcement is expected around April 1, 2026.
